- Home
- MTAL vs SYRE Comparison
MTAL vs SYRE Comparison
Compare MTAL & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTAL
- SYRE
- Stock Information
- Founded
- MTAL 2021
- SYRE 2013
- Country
- MTAL Jersey
- SYRE United States
- Employees
- MTAL N/A
- SYRE N/A
- Industry
- MTAL Blank Checks
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- MTAL Finance
- SYRE Health Care
- Exchange
- MTAL Nasdaq
- SYRE Nasdaq
- Market Cap
- MTAL 1.0B
- SYRE 1.1B
- IPO Year
- MTAL 2021
- SYRE 2016
- Fundamental
- Price
- MTAL $12.22
- SYRE $21.15
- Analyst Decision
- MTAL Hold
- SYRE Strong Buy
- Analyst Count
- MTAL 4
- SYRE 6
- Target Price
- MTAL $12.08
- SYRE $57.60
- AVG Volume (30 Days)
- MTAL 1.1M
- SYRE 835.5K
- Earning Date
- MTAL 11-09-2025
- SYRE 11-06-2025
- Dividend Yield
- MTAL N/A
- SYRE N/A
- EPS Growth
- MTAL N/A
- SYRE N/A
- EPS
- MTAL N/A
- SYRE N/A
- Revenue
- MTAL $321,804,000.00
- SYRE N/A
- Revenue This Year
- MTAL $17.15
- SYRE N/A
- Revenue Next Year
- MTAL $24.95
- SYRE N/A
- P/E Ratio
- MTAL N/A
- SYRE N/A
- Revenue Growth
- MTAL N/A
- SYRE N/A
- 52 Week Low
- MTAL $7.69
- SYRE $10.91
- 52 Week High
- MTAL $13.88
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- MTAL 64.99
- SYRE 73.35
- Support Level
- MTAL $12.20
- SYRE $16.04
- Resistance Level
- MTAL $12.23
- SYRE $17.18
- Average True Range (ATR)
- MTAL 0.02
- SYRE 1.19
- MACD
- MTAL -0.00
- SYRE 0.41
- Stochastic Oscillator
- MTAL 75.00
- SYRE 94.08
About MTAL Metals Acquisition Limited
MAC Copper Ltd is a company focused on operating and acquiring metals and mining businesses in high-quality, stable jurisdictions that are critical in the electrification and decarbonization of the world-wide economy.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.